Momelotinib dihydrochlorideProduct ingredient for Momelotinib

Show full entry for Momelotinib
Name
Momelotinib dihydrochloride
Drug Entry
Momelotinib

Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding.4 First approved by the FDA on September 15, 2023,7 momelotinib is used to treat myelofibrosis.6 Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of cytokines and growth factors. MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis. Momelotinib works to block the JAK-signal transducer and activator of transcription (STAT) signalling pathway, which is aberrant in MF.3,4,5

See full entry for Momelotinib
Accession Number
DBSALT003445
Structure
MOLSDFPDBSMILESInChI
Synonyms
BENZAMIDE, N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-, DIHYDROCHLORIDE / BENZAMIDE, N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-, HYDROCHLORIDE (1:2) / CYT-387 DIHYDROCHLORIDE / CYT387 DIHYDROCHLORIDE / N-(Cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4- yl)benzamide dihydrochloride monohydrate